.After a handful of years in biotech, Mike Quigley, Ph.D., is going back to the pharma layer, taking up the leading science place at Sanofi.Quigley will certainly start Sept. 30 as the French Big Pharma’s main medical police officer as well as global head of research, Sanofi told Fierce Biotech in an emailed declaration.Quigley is actually switching out Frank Nestle, M.D., who left behind Sanofi this spring amid an international overhaul of the company’s R&D unit. Nestle, that spent eight years with the pharma, jumped over to Deerfield Administration, where he currently acts as a companion on the rehabs staff and chief executive officer of the organization’s therapeutic discovery as well as progression functions.
Quigley is going to sign up with Sanofi from a San Francisco-based biotech that’s in stealth, according to his LinkedIn profile page. He is actually presently provided as the provider’s founder, head of state and also CEO.Since August 2021, Quigley has worked as a venture partner at SV Wellness Investors, a health care fund supervisor with present financial investments in biotechs such as BioAge, Cerevance, Dualitas Rehabs and also Nimbus Therapies, to name a few. Quigley previously stored the leading spot at Dualitas, a biotech that stays in stealth, depending on to STAT.The prospective Sanofi innovator additionally previously helmed Therini Bio, an immunotherapy biotech working to create therapies for neurodegenerative ailments driven through vascular problems.Before devoting the last couple of years in biotech, Quigley has an even longer record in Large Pharma, very most lately serving as Gilead’s elderly vice head of state of research the field of biology up until the summertime of 2021.
Prior to that, he appeared more than 4 years throughout different leadership tasks at Bristol Myers Squibb as well as functioned as a clinical director at Johnson & Johnson’s Janssen upper arm just before that.Sanofi said Quigley’s purpose in his brand new part would certainly be actually to “optimize our probability of success by means of superior partnerships around our organization and also past, bringing best-in-class advancement and also creating and also sourcing brand-new industry-leading talent with a commitment to variety,” depending on to an inner memo acquired by STAT.